We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Aprea Therapeutics Inc (APRE) USD0.001

Sell:$5.55 Buy:$6.28 Change: $0.45 (7.76%)
Market closed |  Prices as at close on 20 February 2024 | Switch to live prices |
Sell:$5.55
Buy:$6.28
Change: $0.45 (7.76%)
Market closed |  Prices as at close on 20 February 2024 | Switch to live prices |
Sell:$5.55
Buy:$6.28
Change: $0.45 (7.76%)
Market closed |  Prices as at close on 20 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel synthetic lethality-based cancer therapeutics that target DNA damage response (DDR) pathways. Its synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR), a kinase that plays a critical role in DDR. It is targeting WEE1, a kinase that is a key regulator of multiple phases of the cell cycle. Its lead WEE1 inhibitor product candidate is ATRN-1051. In addition, it has a preclinical research program directed at a second-generation ATR inhibitor, ATRN-354. It is also evaluating combination opportunities within its pipeline, including research on the combination of ATRN-119 and ATRN-1051. Its pipeline includes the clinical-stage asset ATRN-119, an ATR inhibitor that is being evaluated in a Phase 1/2a clinical trial in patients with advanced solid tumors having mutations in defined DDR-related genes.

Contact details

Address:
3805 OLD EASTON ROAD
DOYLESTOWN
18902
United States
Telephone:
+1 (617) 4639385
Website:
https://www.aprea.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
APRE
ISIN:
US03836J2015
Market cap:
$21.78 million
Shares in issue:
3.74 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Oren Gilad
    President, Chief Executive Officer, Director
  • John Hamill
    Chief Financial Officer, Senior Vice President, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.